Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
February 4th, 2021
We describe a xenograft mouse model of breast cancer brain metastasis generated via tail-vein injection of an endogenously HER2-amplified inflammatory breast cancer cell line.
We utilized the tail vein method to generate brain metastasis in mouse models using cell lines derived from patients with inflammatory breast cancer, or IBC, a highly aggressive form of primary breast cancer. The generation of brain metastasis in mouse models typically involves intracardiac or intracarotid arterial injections. However, the tail vein method offers advantage over these techniques as it better mimics the steps of brain metastasis colonization, and is relatively straightforward to perform.
Doctors Xiaoding Hu and Emilly Villodre, both of whom are instructors in my laboratory, will demonstrate the procedure. To detect brain metastases by GFP imaging eight to 10 weeks after tumor cell injection, disinfect the mouse with 70%ethanol and remove the fur from the head and ears. Cut the cervical area of the neck.
Excise and remove the skull to allow the brain to be harvested. Place the brain into a tissue cassette and place the cassette into a container of cold DPBS for no more than one hour. For imaging by stereo microscopy, transfer the brain into a 100-centimeter tissue dish lid under a stereo microscope equipped with a UV light and select the 0.5x objective to allow visualization of the entire brain.
Press live view and focus the view while the brain is in the ventral position. Select the appropriate filter in the software and microscope for the fluorescent marker in the cells, and take a picture. Without moving the sample, switch to brightfield imaging and select the brightfield filter.
Take a picture. Then image the brain in the dorsal position as demonstrated earlier. To analyze the whole brain images, first convert the image files from TIFF to JPEG so they can be opened with any computer that does not have the associated software.
Next, open a pair of brightfield and fluorescent images and select file and merge channels. Select the proper components, click okay, and save the merged image. To quantify the brain tumor area in the fluorescent image, select automatic selection.
Move the arrow to the GFP position area and click to create a selection automatically. Then click again to confirm the selection. All the measurements will be shown.
If more than one GFP positive area can be observed, repeat the measurement with the subsequent area. Brain metastatic lesions can be detected as early as eight weeks after injection by luciferase imaging and stereo fluorescent microscopy. After imaging, portions of the brain metastases can be formalin fixed and processed for hematoxylin and eosin staining to validate the presence of brain metastasis lesions, and for immunohistochemical staining to detect specific protein markers of interest.
When attempting This protocol, it is important to maintain cell viability by keeping the cells on ice for no more than one hour, and to avoid air bubbles in the cell suspension to prevent emboli formation and mouse mortality. Following tail vein injection, we monitor brain metastasis growths and progression with luciferase imaging. After euthanasia, stereo fluorescent microscopy and histology confirmed metastasis lesions.
View the full transcript and gain access to thousands of scientific videos
Overview
This study describes a method for generating brain metastasis in mouse models of inflammatory breast cancer using the tail vein injection technique. This approach mimics the colonization steps of brain metastasis more effectively than traditional methods.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Animal Models
Background
- Inflammatory breast cancer (IBC) is a highly aggressive form of breast cancer.
- Brain metastasis is a common complication in breast cancer patients.
- Traditional methods for inducing brain metastasis include intracardiac and intracarotid injections.
- The tail vein injection method offers a simpler and more representative approach.
Purpose of Study
- To demonstrate a reliable method for creating brain metastasis in mouse models.
- To improve the understanding of the metastatic process in breast cancer.
- To provide a platform for testing therapeutic interventions.
Methods Used
- Utilization of an endogenously HER2-amplified inflammatory breast cancer cell line.
- Injection of cancer cells via the tail vein of mouse models.
- Monitoring of brain metastasis using GFP imaging.
- Disinfection and preparation of mice for imaging post-injection.
Main Results
- Successful generation of brain metastases in the mouse models.
- Demonstration of the tail vein method's effectiveness compared to traditional techniques.
- Visualization of metastases through GFP imaging.
- Establishment of a reproducible model for future research.
Conclusions
- The tail vein injection method is a viable alternative for studying brain metastasis.
- This model can facilitate further research into the mechanisms of metastasis.
- It may aid in the development of new therapeutic strategies for breast cancer.
Frequently Asked Questions
Executive Industry Relevance
Establishing reliable preclinical models of brain metastasis is critical for de-risking therapeutic development in aggressive cancers like inflammatory breast cancer. This tail-vein xenograft model enables mechanistic interrogation of metastatic colonization and supports preclinical evaluation of novel interventions. It addresses a key translational gap by providing a reproducible system for target validation and lead identification in CNS metastasis.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses in HER2-amplified inflammatory breast cancer brain metastasis.
- Operational Value: Provides a consistent xenograft system for functional target validation and pathway de-risking.
Screening & Assay Development
- Scientific Value: Generates quantifiable metastatic burden via bioluminescence and fluorescence for compound screening readiness.
- Operational Value: Standardizes metastatic lesion detection using GFP and luciferase imaging for reproducible assay outputs.
Translational & Preclinical Research
- Scientific Value: Supports disease-relevant modeling of brain metastasis from inflammatory breast cancer for preclinical continuity.
- Operational Value: Facilitates histology and immunohistochemistry validation of metastatic lesions for biomarker alignment.
Pipeline & Workflow Integration
This model integrates into the discovery continuum from target validation through preclinical testing, enabling quantitative assessment of metastatic burden and therapeutic response.
- Discovery Biology: Supports hypothesis testing of metastatic mediators and biological de-risking of CNS tropism.
- Screening: Enables standardized, quantitative readouts for evaluating compound effects on brain metastasis formation.
- Analytics: Provides bioluminescence, fluorescence, and histomorphometric outputs for comparative condition analysis.
- Translational Research: Connects discovery to preclinical validation through consistent metastasis development and lesion characterization.
- Enterprise Reuse: Establishes a reusable xenograft platform for iterative testing of therapeutic strategies in brain metastasis.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in modeling brain metastasis mechanisms and reducing biological ambiguity in target validation.
- Operational Value: Reproducible metastasis generation via tail-vein injection and standardized imaging workflows.
- Strategic Value: Informs go/no-go decisions by enabling preclinical efficacy testing in a clinically relevant metastasis model.
- Portfolio Impact: Supports risk-adjusted advancement of candidates targeting metastatic pathways in aggressive breast cancer.
Implementation Considerations
- Requires expertise in xenograft models, tail-vein injection, and fluorescent imaging techniques.
- Depends on stereomicroscopy with UV light and image analysis software for metastasis quantification.
- Necessitates cross-team standardization for consistent cell preparation, injection, and post-imaging histology.
- Involves adaptation considerations for different cell lines and metastatic timelines across models.
- Limited by the need for technical precision to avoid emboli and ensure cell viability during injection.
